Japanese drugmaker Otsuka Pharmaceuticals (TYO: 4578) is to buy privately-held US biotech Jnana Therapeutics.
Otsuka will pay $800 million to the shareholders of Jnana upon completion of the acquisition, as well as up to an additional $325 million in development and regulatory milestones.
The Tokyo-based firm was attracted to Jnana's novel approach to drug discovery, which is enabled by RAPID, a chemoproteomics platform designed to discover medicines for highly validated but challenging-to-drug targets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze